Nosocomial urinary infection due to Trichosporon asahii. First two cases in Chile;Infección urinaria nosocomial por Trichosporon asahii. Primeros dos casos en Chile

Revista Iberoamericana de Micologia

Volumn 20, Issue 1, 2003, Pages 21-23

  Silva, Víctor ^a   Zepeda, Guillermo ^a   Alvarado, Daniel ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Antifungal susceptibility; Emergent pathogen; Nosocomial urinary tract infection; Trichosporon asahii

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEFTAZIDIME; CYCLOHEXIMIDE; FLUCONAZOLE; IMIPENEM; ITRACONAZOLE; KETOCONAZOLE; SULPERAZON; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CASE REPORT; CHILE; DOSE RESPONSE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; MALE; NONHUMAN; STRAIN DIFFERENCE; TRICHOSPORON ASAHII; URINARY TRACT INFECTION; URINE CATHETER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILE; COMMUNICABLE DISEASES, EMERGING; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FATAL OUTCOME; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; ITRACONAZOLE; KETOCONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIPLE MYELOMA; MYCOSES; OPPORTUNISTIC INFECTIONS; PARKINSON DISEASE; POSTOPERATIVE COMPLICATIONS; TRICHOSPORON; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS; VENTRICULOPERITONEAL SHUNT;

BACTERIA (MICROORGANISMS); TRICHOSPORON ASAHII;

EID: 0038039220     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ellner K, Mc Bride ME, Rosen T, Berman D. Prevalence of Trichosporon beigelii. Colonization of normal perigenital skin. J Med Vet Mycol 1991; 29:99-103.
2. Kalter DC, Tschen JA, Cernoch PL, et al. Genital white piedra: epidemiology, microbiology, and therapy. J Am Acad Dermatol 1986; 14: 982-993.
3. Hoog GS, Guarro J. Atlas of clinical fungi. 2nd ed. Centraalbureau voor Schimmelcultures, Netherlands Universitat Rovira i Virgili, Spain, 1996.
4. Haupt HM, Merz WG, Berschorner WE, Vaughan WP, Saral R. Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis 1983; 147: 199-203.
5. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: clasification, diagnosis, and management. Clin Infect Dis 1993; 17 (Suppl 2): 487-491.
6. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine 1986; 65: 268-279.
7. Kiehn TE, Edwards FF, Armstrong D. The prevalence of yeasts in clinical specimens from cancer patients. Am Soc Clin Pathol 1980; 73: 518-521.
8. Herbrecht R, Koenig H, Waller J, Liu KL, Guého E. Trichosporon infections: clinical manifestations and treatment. J Mycol Med 1993; 3: 129-136.
9. Coquilla BH, Kraus EW. Trichosporonosis (white piedra): four cases in the United States. J Assoc Milit Dermatol 1983; 9: 27-29.
10. Manzella JP, Berman IJ, Kukrika MD. Trichosporon beigelii fungemia and cutaneous dissemination. Arch Dermatol 1982;118:343-345.
11. Fischman O, Pires De Camargo Z, Meireles M. Genital white piedra: An emerging new fungal disease?. Fifth International Conference on mycoses, Pan American Health Organization 1980; 396:70-76.
12. Blancard A, Gouin F, Dunan S, Quilici M. Infection urinaire à Trichosporon inkin. Med Mal Infect 1995; 25: 605-614.
13. Lussier N, Laverdière M, Delorme J, Weiss K, Dandavino R. Trichosporon beigelii funguria in renal transplant recipients. Clin Infect Dis 2000; 31: 1299-1301.
14. Febré N, Silva V, Medeiros EAS, Wey SB, Colombo AL, Fischman O. Microbiological characteristics of yeasts isolated from urinary tracts of intensive care unit patients undergoing urinary catheterization. J Clin Microbiol 1999; 37: 1584-1586.
15. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-340.
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infection. Am J Infect Control 1988; 16: 1-28.
17. Oravcova E, Lacka J, Drgona L, et al. Funguria in cancer patients: analysis of risk factors, clinical presentation and outcome in 50 patients. Infection 1996; 24: 319-323.
18. Wolf DG, Falk R, Hacham M, et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol 2001; 39: 4420-4425.
19. National Committee for Clinical Laboratory Standars. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A. Wayne (PA), National Committee for Clinical Laboratory Standars, 1997.
20. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretative breakpoint for antifungal susceptibility tests: Conceptual framework and analysis of in vitro - in vivo correlation date for fluconazole, itraconazole, and Candida infections. Subcommittee on antifungal susceptibility testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-247.